Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 6 Thoracic 4 Gastrointestinal 4 Tumor-Agnostic 1 Other solid neoplasm 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 25 Specimen Handling 17 Blood Specimen Collection 17 Biopsy 16 Magnetic Resonance Spectroscopy 15 atezolizumab 11 Surveys and Questionnaires 11 Bevacizumab 9 Radiotherapy 8 Radiosurgery 8 Nivolumab 8 Fluorouracil 8 Standard of Care 7 Paclitaxel 7 Irinotecan 7 Gemcitabine 7 Cisplatin 7 olaparib 6 durvalumab 6 Palliative Care 6 Oxaliplatin 6 Leucovorin 6 Cyclophosphamide 6 Carboplatin 6 Capecitabine 6 alectinib 5 abemaciclib 5 Trastuzumab 5 Interviews as Topic 5 Exercise 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × patritumab deruxtecan × Tumor-Agnostic × Clear all

NCT06941272 2026-05-12

MK-9999-01C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡